Blueprint Medicines Announces New Drug Discovery Program Targeting PRKACA Kinase Fusions for the Treatment of Fibrolamellar Carcinoma at 10th International Liver Cancer Association (ILCA) Annual Conference
"Patients with liver cancers have historically suffered from a lack of genomically defined therapeutic options. Our new drug discovery program represents our commitment to patients with orphan cancers," said
FLC is a rare and distinct subtype of liver cancer that typically arises in young adults. Currently, there are no approved therapies, and surgery is the only available treatment option for some patients, but most patients inevitably progress. Research published in 2014 by the laboratory of Dr.
"FLC is a devastating disease, and patients are in great need of effective therapeutic options," said Dr.
The unveiling of the PRKACA program expands
About
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding the estimated number of patients with FLC that harbor the PRKACA fusion; and the timing of clinical data or proof of concept for preclinical and clinical programs, including, without limitation, the timing and type of preliminary clinical data for
Logo - http://photos.prnewswire.com/prnh/20150605/221118LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/blueprint-medicines-announces-new-drug-discovery-program-targeting-prkaca-kinase-fusions-for-the-treatment-of-fibrolamellar-carcinoma-at-10th-international-liver-cancer-association-ilca-annual-conference-300325390.html
SOURCE
Investor Relations: Kristin Williams, Blueprint Medicines Corporation, 617-714-6674, kwilliams@blueprintmedicines.com, or Media Relations: Rachel Hutman, W20 Group, 301-801-5540, rhutman@wcgworld.com